World’s 1st COVID-19 Intranasal Vaccine Will be Launched on January 26

በዓለም የመጀመሪያው የኮቪድ-19 የአፍንጫ ክትባት በመጭው ሐሙስ ጥር ፲፯/17 በሕንድ አገር ይጀምራል

💭 iNCOVACC, the world’s first COVID-19 intranasal vaccine, will be launched on January 26. The intranasal coronavirus vaccine has been developed by India’s Bharat Biotech. Speaking at an event at the Maulana Azad National Institute of Technology (MANIT), Krishna Ella, the company’s chairman and managing director, said, “Our nasal vaccine will be officially launched on January 26, on Republic Day.”

The company, in December 2022, got the approval for the primary 2-dose schedule, and as a heterologous booster dose. Before that, the Central Drugs Standard Control Organisation (CDSCO) had approved the restricted use of the intranasal vaccine in emergency situations in the age group of 18 and above.

💭 University of Oxford Researchers Trialed The Nasal Spray in 45 Healthy Volunteers.

But they found it only led to an immune response in a minority of participants.

This was also weaker than that from the standard injected Covid vaccines

AstraZeneca’s leading Covid nasal spray vaccine does not protect well against the virus, a study has shown — dashing hopes it could replace traditional jabs.

The University of Oxford — which is developing and running trials of the vaccine — said only a minority of patients mounted an immune response.

Even those who did react to the jab had lower antibody levels than someone given a shot-in-the-arm vaccination.

It is another blow for AstraZeneca which has so far failed to break the US vaccine market — after concerns about its original jab’s link to blood clots.

Researchers across the world have placed high hopes on nasal spray vaccines because they may have the potential to stop Covid infections entirely.

It was thought that prompting an immune response directly in the airways would be able to shut the virus down before it spreads to the rest of the body.

But Dr Sandy Douglas, who ran the UK-based AstraZeneca trial, said the spray did not perform ‘as well as we had hoped’.

China and India have already approved nasal spray Covid jabs, although there is no public data on how well they work.

______________